ATRA
Atara Biotherapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.32 EPS, $51.0K rev
Last earnings -9.7% on 2026-03-16
$10.51
▲ +2.84%$10.51▲ +33.38%
over 1Y
L $4.18EODHDH $18.09
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.8%
1W-0.9%
1M-0.3%
3M+129.0%
YTD-40.9%
1Y+33.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Strong net margin (27.1%); but revenue declined -6.3% YoY.
Revenue (FY2025) $121M · FY2025
The read
Middling fundamentals offset by an attractive price (~829% below fair value) — worth a look on the value angle.
Atara Biotherapeutics, Inc. shows $121M in FY2025 revenue (-6.3% YoY), a 27.1% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $8.57M | $129M | $121M |
| Gross profit | — | — | — | — | — |
| Operating income | -$340M | -$281M | -$276M | -$83.4M | $35.9M |
| Net income | -$340M | -$228M | -$276M | -$85.4M | $32.7M |
| Diluted EPS | -$3.63 | -$2.24 | -$65.19 | -$11.41 | $2.57 |
| Net margin | — | — | -3220.9% | -66.2% | 27.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$77.5M
EV / EBITDA2.0
EV / Sales0.6
EV / FCF—
P / FCF—
PEG (trailing)0.03
Earnings yield38.0%
FCF yield-59.3%
Quality & risk
ROIC (est.)—
Free cash flow-$50.9M
Total debt—
Net cash$8.48M
Altman Z-Score-127.35 distress
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+39.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-05-01). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-222026-06-26open ↗4Period ending 2026-06-112026-06-15open ↗3Period ending 2026-06-112026-06-15open ↗S-8Filing2026-06-12open ↗8-KPeriod ending 2026-06-092026-06-12open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗144Filing2026-05-18open ↗144Filing2026-05-18open ↗
Frequently asked
- Is Atara Biotherapeutics, Inc. (ATRA) a buy?
- ATRA currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Strong net margin (27.1%); but revenue declined -6.3% YoY.
- What is ATRA's fair value?
- A Modified-Graham model based on ATRA's SEC fundamentals estimates a fair value of about $97.66. It is an estimate from reported earnings, not a price target.
- Is ATRA overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, ATRA currently appears undervalued relative to its SEC-grounded earnings power.
- What is Atara Biotherapeutics, Inc.'s quality score?
- ATRA scores 73.86274509803921/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001604464, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 8:17:52 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.